Wei Yin

Title: Innovations by Wei Yin: A Pioneer in Isoxazole Derivatives

Introduction

Wei Yin is an accomplished inventor based in Chengdu, China, making significant contributions to the field of biopharmaceuticals. His innovative work has led to the development of specialized compounds that hold promise for treating complex medical conditions.

Latest Patents

Wei Yin holds a patent for an isoxazole derivative, which focuses on the preparation method and its various uses. This invention particularly centers around a farnesoid X receptor (FXR) agonist compound. The patent details not only the compound itself but also its stereoisomers, tautomers, polymorphs, solvates (including hydrates), and pharmaceutically acceptable salts. Additionally, it covers esters, metabolites, N-oxides, and their chemically protected forms and prodrugs. The significance of this invention lies in its application for treating FXR-mediated diseases or conditions, through an innovative preparation method, intermediate compounds, and pharmaceutical compositions and kits.

Career Highlights

Wei Yin is affiliated with Sichuan Kelun Biotech Biopharmaceutical Co., Ltd., where he continues to pioneer advancements in pharmaceutical research. His dedication and innovative thinking have positioned him as a key player in the company, contributing to the development of effective therapeutic solutions.

Collaborations

At Sichuan Kelun Biotech Biopharmaceutical Co., Ltd., Wei works alongside talented colleagues, including Jinming Liu and Jiaqiang Cai. These collaborations enhance the research environment and foster innovative approaches to complex scientific challenges.

Conclusion

Wei Yin's contributions to the field of pharmaceuticals, particularly through his patent involving isoxazole derivatives, exemplify the impactful role of inventors in advancing medical science. His ongoing efforts at Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. highlight the importance of innovation in addressing health-related issues and improving patient outcomes.